派格生物医药-B今日盘中大涨28.96%，引起了市场的广泛关注。
消息面上，此次大涨主要得益于公司核心产品派达康（维培那肽注射液）的商业化合作取得显著进展。公司此前与腾瑞制药就派达康在中国大陆地区签署了独家商业化战略合作协议，双方确立了累计销售规模超100亿元人民币的核心目标，腾瑞制药将支付合计约1.4亿港币的权益金。
此外，方舟健客与腾瑞制药已完成战略签约，派达康将于近期在其互联网医院平台全网首发，这标志着该产品的商业化落地进程正在加速。这些积极的市场消息持续催化了投资者的乐观情绪，推动了股价的强劲表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.